Volasertib is a polo-like kinase (Plk) inhibitor being developed by Boehringer Ingelheim for the treatment of AML. By targeting Plk, the inhibiter can cause cell-cycle arrest and apoptosis.
Volasertib is Boehringer Ingelheim’s Phase III candidate that is being developed to treat patients aged ≥65, who are ineligible for standard induction therapy. By targeting this difficult-to-treat population, volasertib is likely to see good uptake as it expands upon limited treatment options available for these patients. However, volasertib would compete with Synta Pharmaceuticals’ Phase III ganetespib, which is also targeting the same population. Phase II clinical data for volasertib are more promising than for ganetespib, and Boehringer Ingelheim is seeking to demonstrate volasertib’s efficacy in a large-scale Phase III clinical trial.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 volasertib : Acute myeloid leukemia
LIST OF FIGURES
6 Figure 1: Volasertib – SWOT analysis for AML
7 Figure 2: Datamonitor Healthcare’s drug assessment summary for volasertib in AML
8 Figure 3: Datamonitor Healthcare’s drug assessment summary for volasertib in AML
LIST OF TABLES
4 Table 1: Volasertib drug profile for acute myeloid leukemia
5 Table 2: Ongoing clinical trial development for volasertib in AML
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726